Skip to content

Single-cell sequencing project for peripheral blood immune cells of patients with heat stroke

Single-cell sequencing project for peripheral blood immune cells of patients with heat stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079731
Enrollment
Unknown
Registered
2024-01-10
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heat stroke

Interventions

Control Group:None

Sponsors

The First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. between 18 and 75 years of age, regardless of gender. 2. History of the following during ICU stay (patients exposed to high temperature and humidity, patients performing intense exercise) and meeting the diagnostic criteria of the Expert Consensus on Standardized Treatment of Heat Stroke (core temperature > 40°C, central nervous system abnormalities, including extreme fatigue, persistent headache, motor incoordination, inappropriate behavior, impaired judgment, altered mental status, convulsions, delirium or coma) and possible Patients with new onset (less than 48 hours after diagnosis) pyrexia with heavy sweating or no sweating, or with life-threatening multiorgan damage (e.g., nausea, vomiting and syncope, abdominal pain, diarrhea, acute respiratory distress syndrome, heat-related liver function abnormalities, hypotension, tachycardia and heart failure, renal failure, coagulation abnormalities, rhabdomyolysis, etc.).

Exclusion criteria

Exclusion criteria: 1. women during pregnancy. 2. Immunosuppressed status including history of malignancy, long-term use of hormonal or immunosuppressive drugs (including antifungal and antiviral drugs), HIV or other immunodeficiency diseases, history of organ transplantation. 3. use of immune-enhancing drugs (e.g., thymidine, interleukin, gammaglobulin, etc.). 4. ICU stay less than 24 hours

Design outcomes

Primary

MeasureTime frame
Single-cell transcriptome sequencing of peripheral blood CD45+ cells;

Secondary

MeasureTime frame
Sequential Organ Failure Assessment;inflammatory cytokine;

Countries

China

Contacts

Public ContactHongjun Kang

The First Medical Center of Chinese PLA General Hospital

doctorkang301@163.com+86 10 6693 8248

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026